Rezultati - Jeroen J.W.M. Janssen

Refine Results
  1. 1
    Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment

    Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment od David C. de Leeuw, Gert J. Ossenkoppele, Jeroen J.W.M. Janssen

    Izdano 2022
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia

    Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia od G.J. Ossenkoppele, Jeroen J.W.M. Janssen, Arjan A. van de Loosdrecht

    Izdano 2015
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation

    Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation od Linda Bouwman, Corien Eeltink, Otto Visser, Jeroen J.W.M. Janssen, Jolanda Maaskant

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies

    Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies od Mila S. Griffioen, David C. de Leeuw, Jeroen J.W.M. Janssen, Linda Smit

    Izdano 2022
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    MRD Tailored Therapy in AML: What We Have Learned So Far

    MRD Tailored Therapy in AML: What We Have Learned So Far od Lok Lam Ngai, Angèle Kelder, Jeroen J.W.M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos

    Izdano 2021
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel

    Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel od Martin C. Müller, Francisco Cervantes, Henrik Hjorth‐Hansen, Jeroen J.W.M. Janssen, Dragana Milojković, Delphine Réa, Gianantonio Rosti

    Izdano 2017
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors

    Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors od Andreas Hochhaus, Massimo Breccia, Giuseppe Saglio, Valentín García‐Gutiérrez, Delphine Réa, Jeroen J.W.M. Janssen, Jane F. Apperley

    Izdano 2020
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up od Michael Heuser, Yishai Ofran, Nicolas Boissel, S. Brunet Mauri, Charles Craddock, Jeroen J.W.M. Janssen, Agnieszka Wierzbowska, Christian Buske

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Treatment outcome in a population-based, ‘real-world’ cohort of patients with chronic myeloid leukemia

    Treatment outcome in a population-based, ‘real-world’ cohort of patients with chronic myeloid leukemia od Inge G.P. Geelen, Noortje Thielen, Jeroen J.W.M. Janssen, Mels Hoogendoorn, Tanja J.A. Roosma, Sten P. Willemsen, Otto Visser, Jan J. Cornelissen, Peter E. Westerweel

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

    High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome od Martine E.D. Chamuleau, Arjan A. van de Loosdrecht, Corine J. Hess, Jeroen J.W.M. Janssen, A. Zevenbergen, R Delwel, Peter J.M. Valk, Bob Löwenberg, G.J. Ossenkoppele

    Izdano 2008
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

    High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome od Martine E.D. Chamuleau, Arjan A. van de Loosdrecht, C. J. Hess, Jeroen J.W.M. Janssen, A. Zevenbergen, Ruud Delwel, Peter J.M. Valk, Bob Löwenberg, G.J. Ossenkoppele

    Izdano 2008
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach

    The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach od Geneviève I. C. G. Ector, Peter E. Westerweel, Rosella Hermens, Karin AE Braspenning, Barend Heeren, Oscar MF Vinck, Jan JM de Jong, Jeroen J.W.M. Janssen, Nicole M. A. Blijlevens

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin

    Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin od Baoxu Pang, Xiaohang Qiao, Lennert Janssen, Arno Velds, Tom A. Groothuis, Ron Kerkhoven, Marja Nieuwland, Huib Ovaa, Sven Rottenberg, Olaf van Tellingen, Jeroen J.W.M. Janssen, Peter C. Huijgens, Wilbert Zwart, Jacques Neefjes

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

    Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification od Inge van der Werf, Anna Wojtuszkiewicz, Manja Meggendorfer, Stephan Hütter, Constance Baer, Martijn W. Heymans, Peter J.M. Valk, Wolfgang Kern, Claudia Haferlach, Jeroen J.W.M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos, Torsten Haferlach

    Izdano 2021
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON)

    Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato... od Noortje Thielen, Bronno van der Holt, Jan J. Cornelissen, Gregor Verhoef, Titia Gussinklo, Bart J. Biemond, Simon Daenen, Wendy Deenik, Rien van Marwijk Kooy, Eefke Petersen, Willem M. Smit, Peter J.M. Valk, Gert J. Ossenkoppele, Jeroen J.W.M. Janssen

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines

    Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines od Carolien van Alphen, Jacqueline Cloos, Robin Beekhof, David G. J. Cucchi, Sander R. Piersma, Jaco C. Knol, Alex A. Henneman, Thang V. Pham, Johan van Meerloo, Gert J. Ossenkoppele, Henk M.W. Verheul, Jeroen J.W.M. Janssen, Connie R. Jiménez

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial

    Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial od Evelien Kneppers, Bronno van der Holt, Marie José Kersten, Sonja Zweegman, Ellen Meijer, Gerwin Huls, Jan J. Cornelissen, Jeroen J.W.M. Janssen, Cynthia Huisman, Petra Cornelisse, Cheryl P. Bruijnen, Maarten E. Emmelot, Pieter Sonneveld, Henk M. Lokhorst, Tuna Mutis, Monique C. Minnema

    Izdano 2011
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia

    Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia od Jesse M. Tettero, Maaike E. Heidinga, Tim R. Mocking, Glenn Fransen, Angèle Kelder, Willemijn J. Scholten, Alexander N. Snel, Lok Lam Ngai, Costa Bachas, Arjan A. van de Loosdrecht, Gert J. Ossenkoppele, David C. de Leeuw, Jacqueline Cloos, Jeroen J.W.M. Janssen

    Izdano 2024
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study

    Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study od Henk M. Lokhorst, Bronno van der Holt, Jan J. Cornelissen, Marie José Kersten, Marinus van Oers, Reinier Raymakers, Monique C. Minnema, Sonja Zweegman, Jeroen J.W.M. Janssen, Mark Zijlmans, Gerard M.J. Bos, Nicolaas Schaap, Shulamiet Wittebol, Okke de Weerdt, Rianne Ammerlaan, Pieter Sonneveld

    Izdano 2012
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

    Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial od Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saußele, Perttu Koskenvesa, Leif Stenke, Satu Mustjoki, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf‎, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde‐Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth‐Hansen, Jeroen J.W.M. Janssen, Ulla Olsson‐Strömberg

    Izdano 2024
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: